Braun Martina / Conti Carlo / Künzler Oliver

GLI - Pricing & Reimbursement 2022

25.08.22

GLI - Pricing & Reimbursement 2022, Fifth Edition, p. 218 - 227

Stalder Beat

Kommentar zu Art. 34 - 41 HMG

08.12.21

In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

Beck Filippo Th. / Braun Martina

Kommentar zu Art. 17 HMG

08.12.21

In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

Conti Carlo

Kommentar zu Art. 16a - 16c HMG

08.12.21

In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

Beck Filippo Th.

Kommentar zu Art. 17a HMG

08.12.21

In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

Schmid Gerhard / Uhlmann Felix

Kommentar zu Art. 14 - 16, 65 HMG

08.12.21

In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

Conti Carlo / Herzfeld Adam / Künzler Oliver

The Pharma Legal Handbook

06.09.21

Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms · Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs · Orphan Drugs and Rare Diseases · Localization · Biosimilars and Biologics | Pharma Boardroom, 2021

Braun Martina / Conti Carlo / Künzler Oliver

GLI - Pricing & Reimbursement 2021

23.08.21

GLI – Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204

Braun Martina

Beurteilung der Wirtschaftlichkeit von Arzneimitteln im Rahmen der dreijährlichen Überprüfung

20.10.20

Urteil Bundesverwaltungsgerichts BVGer C-6093/2018 vom 17. März 2020, LSR 2020, S. 163

Braun Martina / Conti Carlo / Künzler Oliver

GLI - Pricing & Reimbursement 2020

24.08.20

Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.